Summary

Eligibility
for people ages 18-75 (full criteria)
Location
at UCSD
Dates
study started
completion around

Description

Summary

The study is a randomized trial of two different screening methods for early detection of liver cancer in patients with cirrhosis of the liver. The goal of PREMIUM is to compare an abbreviated version of the diagnostic gold standard for HCC (aMRI) +AFP to the standard-of-care screening (US+AFP) in patients at high risk of developing HCC. The investigators hypothesize that HCC will be detected at earlier stages, allowing for more curative treatments and resulting in a reduction in HCC-related mortality.

Official Title

CSP #2023 - Preventing Liver Cancer Mortality Through Imaging With Ultrasound vs. MRI (The PREMIUM Study)

Details

Keywords

Carcinoma, Hepatocellular, Cirrhosis, hepatic, oncology, liver, chronic diseases; health services and systems, prospective, randomized, clinical trial, magnetic resonance imaging; ultrasonography, cirrhosis; liver cancer, Liver Neoplasms, Hepatocellular Carcinoma, Fibrosis, Abbreviated Magnetic Resonance Imaging with serum AFP, Abdominal Ultrasound Screening with serum AFP

Eligibility

Locations

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
VA Office of Research and Development
ID
NCT05486572
Study Type
Interventional
Participants
Expecting 4700 study participants
Last Updated